Class / Patent application number | Description | Number of patent applications / Date published |
530399000 | Hormones, e.g., prolactin, thymosin, growth factors, etc. | 64 |
20080227960 | Crystal structure of estrogen receptor-beta complex and uses thereof - This invention is directed to the crystal structure of Estrogen Receptor-β (ER-β) complexed with genistein, and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of ER-β, which may be useful as novel chemotherapeutic agents. | 09-18-2008 |
20080293922 | BETA-AMYLOID BINDING FACTORS AND INHIBITORS THEREOF - The present invention relates to a VEGF polypeptide that binds to Aβ. The present invention also relates to a compound that sequesters Aβ. And conversely, the invention relates to a compound that sequesters VEGF. Thus, the present invention also relates to a method of screening for a compound that inhibits the binding of VEGF to Aβ, and thus relates to prevention and treatment of Alzheimer's Disease. | 11-27-2008 |
20080293923 | CRYSTAL STRUCTURE OF THE COMPLEX OF HEPATOCYTE GROWTH FACTOR BETA CHAIN WITH MET RECEPTOR AND METHODS OF USE - The disclosure provides a crystal structure of a complex of the HGF β-chain with am extracellular fragment of the Met receptor, as well as use of the crystal structure in the design, identification, and selection of ligands that modulate the Met Receptor and the interaction of HGF with the Met receptor. | 11-27-2008 |
20080319174 | CHIMERA HUMANIZED VASCULAR ENDOTHELIAL GROWTH FACTOR - An object of the present invention is to provide a chimera VEGF-E having a reduced antigenicity while maintaining the activity of VEGF-E. The present invention provides a chimera protein having an activity of growing vascular endothelial cells, which is obtained by substituting a part of the sequence of a VEGF analogous protein having an activity of vascularization that binds to KDR (VEGF receptor-2) but does not bind to Flt-1 (VEGF, receptor-1) with a corresponding sequence of a human-derived VEGF analogous protein. | 12-25-2008 |
20090043078 | GDF-5 PROTEIN STORAGE - Improved compositions and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an aqueous solution of GDF-5 and a biocompatible acid, such as hydrochloric, acetic, phosphoric, or trifluoroacetic acid, wherein the solution has a pH of from about 3.0 to about 3.6, thereby providing for improved stability of the GDF-5 protein during handling and prolonged storage at reduced temperatures. | 02-12-2009 |
20090105463 | Compositions of and Methods of Using Oversulfated Glycosaminoglycans - The invention relates, in part, to compositions comprising glycosaminoglycans, fragments of glycosaminoglycans or glycosaminoglycan fractions. The compositions provided can be used in various methods of modulating FGF and/or VEGF activity. The method can be in vitro or in vivo methods. Therefore, the invention also relates, in part, to methods of treating a subject with the compositions provided. | 04-23-2009 |
20090221805 | Complex polymere amphiphile-PDGF - Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups. | 09-03-2009 |
20090240039 | Polypeptide fusion - A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-β and TPO, linked to a subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins. | 09-24-2009 |
20090286965 | MUTANT GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITIES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed is a mutant protein having an altered fibroblast growth factor receptor specificity, which is produced by deleting one or more amino acid residues from the N-terminus of the amino acid sequence of naturally secreted fibroblast growth factor 18. The protein mutant can be used in a pharmaceutical composition for regulating hair regeneration or growth or a pharmaceutical composition for regulating bone or cartilage formation. | 11-19-2009 |
20100029909 | COMPOSITIONS AND METHODS COMPRISING MAGNETIC RESONANCE CONTRAST AGENTS - The present invention relates to compositions and methods for imaging with magnetic resonance contrast agents. In particular, the present invention provides targeted contrast agents for selective imaging. | 02-04-2010 |
20100105878 | Hybrid Hepatocyte Growth Factor Gene Having High Expression Efficiency of Two Heterotypes of Hepatocyte Growth Factor - The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases. | 04-29-2010 |
20100121036 | METHOD FOR THE PRODUCTION OF INSULIN-LIKE GROWTH FACTOR-1 - Method for the production of IGF-I, characterized by cultivating a prokaryotic host cell comprising an expression vector containing a nucleic acid encoding a fusion protein comprising said IGF-I N-terminally linked to the C-terminus of a propeptide, whereby said propeptide ends C-terminally with amino acids -Y-Pro, wherein Y is selected from the group consisting of Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, or Pro-Arg-Pro, recovering and cleaving said fusion protein with IgA protease, and recovering said IGF-I. IGF-I is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease. | 05-13-2010 |
20100121037 | METHOD FOR SELECTIVE FRACTIONATION OF GROWTH FACTORS FROM DAIRY PRODUCTS - The invention relates to the general field of protein fractionation, and more particularly to the selective fractionation of growth factor from dairy products, such as milk, whey and colostrum. There is provided methods for the selective fractionation of TGF-β, lactoferrin and bovine serum albumin. | 05-13-2010 |
20100130730 | PROTEIN FORMULATIONS FOR USE AT ELEVATED TEMPERATURES - Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature. | 05-27-2010 |
20100145033 | NOVEL ORTHOGONAL PROCESS FOR PURIFICATION OF RECOMBINANT HUMAN PARATHYROID HORMONE (RHPTH) (1-34) - The present invention discloses a process for the preparation of rhPTH (1-34) also known as teriparatide by con-struction of a novel nucleotide, as an NcoI.IXhoI fragemt as set forth in SEQ. ID. No.:1 encoding a chimeric fusion protein as set forth in SEQ.ID. No.:2 comprising of a fusion partner consisting of 41 amino acids belonging to | 06-10-2010 |
20100210826 | HGF BETA CHAIN VARIANTS - The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators. | 08-19-2010 |
20100261888 | Recombinant Production of Heparin Binding Proteins - A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate. | 10-14-2010 |
20100292444 | Novel Prolactin Compounds - The present invention relates to prolactin analogues, which analogues have increased resistance to deamidation. | 11-18-2010 |
20110028699 | Agent for Treating Skin Aging and Scars - It is to provide an agent for preventing and treating skin aging, or an agent for treating skin scar that can exert a sufficient effect. An agent for preventing and treating skin aging comprising bFGF for treating aging of the skin that is administered intradermally or subcutaneously, or an agent for treating skin scar comprising bFGF for treating scar of skin that is administered intradermally or subcutaneously is utilized. Preferred examples of aging of skin include skin wrinkle, pigmented spot, sagging skin, rough skin, skin thinning, decrease of skin viscoelasticity, etc., and preferred examples of scar include keloid, hypertrophic scar, scar contracture, etc. | 02-03-2011 |
20110082285 | TRANSGENIC RODENTS HAVING NGF BETA GENE MUTANTS AND ITS PREPARATION METHODS, THE PREPARATION METHODS OF THE CORRESPONDING MUTANT PROTEINS AND THE RESULTING MUTANT PROTEINS - Transgenic rodents having NGF beta gene mutants in their genomes express NGF beta mutant proteins. The preparation methods of the transgenic rodents, the methods of utilizing the transgenic animals to prepare NGF beta mutant proteins and the resulting NGF beta mutant proteins are provided. The transgenic rodents are useful in preparing human NGF and in the study of the functions of NGF beta mutants and their receptors in the whole animal level, and also useful for screening and purifying NGF beta mutants which have high activity and high security. | 04-07-2011 |
20110152507 | PROCESSES FOR REFOLDING OF INSULIN - The invention provides processes for obtaining a precursor for insulin, analogs or derivatives thereof having correctly bonded cystine bridges. The process involves solubilizing a precursor of insulin, insulin analog or derivatives in an aqueous solution or a buffer containing cysteine or cysteine hydrochloride and one or more of chaotropic auxiliary. The solubilized precursors are refolded by adding diluent to the solubilized mixture (reverse dilution). Further, the solubilized precursors, wherein the concentration of precursor in reaction mixture is more than 0.65 g/litre can also be refolded by diluting the reaction mixture with a diluent optionally comprising about 5-40% v/v of one or more of alcoholic or aprotic solvents. | 06-23-2011 |
20110160441 | OPTIMIZED PURIFICATION PROCESS OF RECOMBINANT GROWTH FACTOR PROTEIN - A process for the production of a purified recombinant GDF-5 related protein in prokaryotes comprises the steps of bacterial cell disruption and inclusion body solubilization to obtain a solubilized monomer of a GDF-5 related protein, said process characterized by a) disruption of bacterial cells with a high pressure homogenizer at a disruption pressure between 800 and 900 bar; and/or b) treatment of the recovered inclusion bodies with a denaturing solubilization buffer comprising L-arginine. | 06-30-2011 |
20110172401 | Modified FGF-21 Polypeptides and Their Uses - Modified FGF-21 polypeptides and uses thereof are provided. | 07-14-2011 |
20110196134 | Process for PEGylation of Proteins - The present invention relates to a process for improving pegylation reaction yield of r-metHuG-CSF comprising conjugating r-metHuG-CSF to a PEG aldehyde at a free amine moiety at the N terminal end on the G-CSF in presence of a reducing agent in a pegylation buffer solution comprising a polyol having the formula C | 08-11-2011 |
20110213131 | Method of Acylating a Peptide or Protein - A method has for selectively acylating an amino group in a peptide or protein which has two or more reactive nucleophilic functional groups is described. | 09-01-2011 |
20110213132 | PRODUCTION OF NGF IN PLANT - The invention relates to genetically modified plants capable of producing a human recombinant protein Nerve Growth Factor, either in the form of pre-pro-protein or in the mature form and parts and differentiated and undifferentiated tissues thereof. The invention relates, also, to methods for the transformation of said plants in a transient way and methods for the transformation of said plants and tissues in a stable or transient way, methods for the recombinant protein purification from crude extract of proteins derived from plant tissue of said plants. | 09-01-2011 |
20110224410 | Buffers for Controlling the pH of Bone Morphogenetic Proteins - The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation. | 09-15-2011 |
20110245474 | METHODS FOR G-CSF PRODUCTION IN A PSEUDOMONAS HOST CELL - The present invention relates to the field of recombinant protein production in bacterial hosts. It further relates to expression of soluble, active recombinant protein by using secretion signals to direct the protein to the periplasmic space of a bacterial cell. In particular, the present invention relates to a production process for obtaining soluble hG-CSF protein from a bacterial host. | 10-06-2011 |
20110263834 | Simple Method for Simultaneous Removal of Multiple Impurities from Culture Supernatants to Ultralow Levels - This invention is directed to methods for removing, preferably simultaneously and in one step, multiple impurities form crude culture samples, and, in particular, the removal of media components, protein, nucleic acids, lipids, and lipopolysaccharides to ultralow levels. Preferably the purification process comprises: (1) binding of the target substance containing one or more contaminants to a chromatography matrix; (2) washing the bound target substance with one or more buffers containing a synergistic combination of a lyotropic agent or organic solvent, a detergent, and a salt component; and (3) desorbing the target substance from the chromatography matrix, so that the eluate contains ultra low levels of contaminants. The reduction of impurities that can be achieved is preferably 91-99.9% as compared to the amount of impurities in the target substance before purification. The invention is also directed to the targets products that have been so purified. | 10-27-2011 |
20110263835 | RECOMBINANT NELL PROTEIN PRODUCTION - The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide. | 10-27-2011 |
20110269944 | HGF PRECURSOR PROTEIN VARIANT AND ACTIVE PROTEIN THEREOF - An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an α chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the α chain are deleted, and a β chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the β chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action. | 11-03-2011 |
20110294990 | Refolding of Recombinant Proteins - Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer. | 12-01-2011 |
20110301340 | Toxins and Radionuclides Coupled to IGF-1 Receptor Ligands for Treatment of Cancer - The invention provides an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide for treatment of cancer is provided. A method of treating cancer using the IGF-1 receptor ligand carrying a therapeutic radionuclide is also provided. An anti-cancer therapeutic agent containing an IGF-1 receptor ligand linked to a toxin is also provided, as are methods of using the toxin conjugates for treatment of cancer. | 12-08-2011 |
20120253023 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 10-04-2012 |
20120309944 | Growth Hormones With Prolonged In-Vivo Efficacy - The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy. | 12-06-2012 |
20130005951 | PROCESS FOR PREPARING FGF21 WITH LOW DEGREE OF O-GLYCOSYLATION - Expression of FGF21 in a | 01-03-2013 |
20130030161 | PROCEDURE FOR OBTAINING A COMPOSITION CONTAINING GROWTH FACTORS FROM A BLOOD COMPOUND, AND COMPOSITION OBTAINED BY SAID PROCEDURE - Procedure for obtaining a composition that contains growth factors, which comprises the steps of heat-treating a platelet-rich plasma or the supernatant of a platelet-rich plasma that contains released growth factors in order to increase its temperature, for eliminating the complement and reducing the immunoglobulins present therein, and lyophilizing the plasma or supernatant in order to obtain a final dry composition that can easily be transported, handled and stored, thereby facilitating periodic or chronic treatments with blood compounds. It has been shown that when the final dry composition is resuspended, a once again humid composition is obtained that maintains its biological properties intact. | 01-31-2013 |
20130060012 | METHOD FOR PURIFYING BONE MORPHOGENETIC PROTEIN - The present invention relates to a method for purifying a protein belonging to the TGF-β, superfamily, preferably BMP, and more preferably BMP-2. According to the invention, the number of purification steps is reduced and the purification process is simplified, compared to the conventional BMP-2 purification method. Thus, the time required for purification can be shortened and the cost can be reduced. In addition, the invention solves the problem that as the time for purification increases and the number of purification steps increases, BMP-2 is degraded by protease or lost during purification steps, resulting in a decrease in the final yield of BMP-2. Thus, the invention increases the final yield of BMP-2. In addition, according to the invention, although the number of purification steps is reduced, BMP-2 having high purity is obtained in high yield by optimizing and using filtrations and chromatographies, and columns, types and concentrations of buffers, and a cut-off size of membrane used in diafiltration, which are different from those of the conventional BMP-2 purification method. | 03-07-2013 |
20130123474 | Refolding of Recombinant Proteins - Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer. | 05-16-2013 |
20130184443 | Methods for Preparing Conjugates - The present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a conjugate having a degradable linkage. The conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods for delivering such compositions are also provided. | 07-18-2013 |
20130211054 | METHOD FOR PURIFYING HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR FROM RECOMBINANT E. COLI - The present invention provides a method for purifying a large amount of human granulocyte-colony stimulating factors (hG-CSFs) from a recombinant | 08-15-2013 |
20130217867 | Recombinant Production of Heparin Binding Proteins - A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate. | 08-22-2013 |
20130345409 | GROWTH FACTOR - VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications. | 12-26-2013 |
20140058068 | Novel GH-RH analogs with potent agonistic effects - There are provided a novel series of peptide analogs of hGH-RH(1-29)NH | 02-27-2014 |
20140081006 | METHOD FOR PRODUCING MULLERIAN INHIBITOR SUBSTANCE IN PLANTS - The present invention provides, in one aspect, a method for producing Mullerian Inhibitor Substance in a plant comprising incubating or growing a plant into which has been introduced or infiltrated a nucleic acid construct comprising, consisting or consisting essentially of a nucleic acid sequence encoding a Mullerian Inhibitor Substance fusion protein that comprises a fusion protein partner that induces the formation of a protein body in a plant, preferably, wherein the step of introducing or infiltrating the plant is performed prior to the incubating or growing step. | 03-20-2014 |
20140107324 | Growth Hormones with Prolonged In-Vivo Efficacy - The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy. | 04-17-2014 |
20140171625 | CARDIOTROPHIN RELATED MOLECULES FOR ENHANCED THERAPEUTICS - The invention provides novel polypeptides having at least one biological activity of cardiotrophin and improved biologic drug-like properties, and polynucleotides encoding the polypeptides of the invention. The polypeptides of the invention can be used therapeutically, such as, for example, in methods of tissue regeneration. | 06-19-2014 |
20140213776 | METHODS AND COMPOSITIONS COMPRISING HUMAN RECOMBINANT GROWTH AND DIFFERENTIATON FACTOR-5 (RHGDF-5) - Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhGDF-5 protein. Methods for production and high expression of rhGDF-5 protein are disclosed herein. The methods of enhancing production and protein expression of rhGDF-5 protein as disclosed are cost-effective, time-saving and are of manufacturing quality. | 07-31-2014 |
20140249299 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 09-04-2014 |
20140256917 | COMPOSITIONS AND METHODS FOR OSTEOGENIC GENE THERAPY - The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair). | 09-11-2014 |
20140336367 | RECOMBINANT NEL-LIKE (NELL) PROTEIN PRODUCTION - The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide. | 11-13-2014 |
20150031864 | Modified Adiponectin Polypeptides and Their Uses - Modified adiponectin polypeptides and uses thereof are provided. | 01-29-2015 |
20150051382 | USE OF URODILATIN FOR PREPARING A MEDICAMENT FOR THE TREATMENT OF CARDIOVASCULAR, RENAL, PULMONARY AND NEURONAL SYNDROME WHILE AVOIDING A REBOUND - Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound, wherein said medicament for the delivery of urodilatin is suitable in a first quantity for a first period of at least 48 hours, followed by delivery over a second period of at least 12 hours with successive reduction of said first quantity continuously or gradually to 0 ng/kg/min. | 02-19-2015 |
20150094457 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES - Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses. | 04-02-2015 |
20150126715 | Highly Glycosylated Long-Acting Human Growth Hormone Protein and Production Method for Same - The present invention relates to a long-acting human growth hormone NexP-hGH protein and its production method. More specifically, it relates to a specific isoform of long-acting human growth hormone NexP-hGH protein in which human growth hormone is fused with a highly glycosylated alpha-1 antitrypsin mutant whereby long-acting properties in vivo are increased. The present invention also relates to a high-purity purification method for NexP-hGH, which includes the steps of: (a) carrying out anion-exchange resin chromatography on a biological emulsion comprising NexP-hGH in which human growth hormone is fused with an alpha-1 antitrypsin mutant; (b) carrying out hydrophobic resin chromatography on the biological emulsion comprising NexP-hGH, or on the eluate produced in step (a); and (c) carrying out affinity chromatography, entailing packing with a resin to which anti-alpha-1 antitrypsin antibody fragments are attached, on the biological emulsion comprising NexP-hGH and on the eluate produced in step (a) or step (b). | 05-07-2015 |
20150141627 | METHOD FOR ANTIGEN DELIVERY - The present invention relates to a novel method for an antigen and/or bioactive molecule delivery and a composition that functions in the antigen and/or bioactive molecule delivery comprising the ASC speck carrier and the antigen and/or bioactive molecule, carried by the ASC speck carrier. | 05-21-2015 |
20150315259 | METHOD OF PRODUCING A RECOMBINANT PEPTIDE - Methods of producing a recombinant peptide, such as vessel dilator peptide (VSDL), are disclosed, including a particular method involving expressing a fusion polypeptide comprising concatemeric repeats of the peptide wherein the peptide is flanked by peptide cleavage sites, and cleaving the fusion polypeptide at the peptide cleavage sites with a cleaving agent(s) so as to release the peptide from the fusion polypeptide. Expression constructs and host cells for producing the fusion polypeptide and purification methods for the recombinant peptide are also disclosed. | 11-05-2015 |
20150344591 | Sialic Acid Derivatives - An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids. | 12-03-2015 |
20160039895 | POLYPEPTIDES TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND ALPHA V BETA 3 INTEGRIN - Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization. | 02-11-2016 |
20160039896 | POLYPEPTIDES TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND ALPHA V BETA 3 INTEGRIN - Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization. | 02-11-2016 |
20160137690 | REFOLDING OF RECOMBINANT PROTEINS - Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer. | 05-19-2016 |
20160159935 | Fractionation of Charged Polysaccharide - Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals. | 06-09-2016 |
20160159936 | Fractionation of Charged Polysaccharide - Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals. | 06-09-2016 |
20160251405 | APPLICATION OF METRNL PROTEIN IN PREPARING HYPOLIPIDEMIC, HYPOGLYCEMIC MEDICINE | 09-01-2016 |